Skip to main content
. 2016 Apr 12;24(6):1106–1116. doi: 10.1038/mt.2016.60

Figure 3.

Figure 3

Internalization and biological effects of conjugated aptamers in PANC-1 cells. (a) Cy3-labeled P19- or P1-conjugated C/EBPα-saRNAs were incubated with PANC-1 cells. Red: Cy3-labeled RNA, Blue: Hoechst 33342. (b) Relative transcript expression (qPCR) for C/EBPα mRNA and (c) p21 mRNA was quantified by real-time PCR. CEBPA expression increased fivefold (P = 0.029) and p21 increase 57.6-fold (P = 0.033) by P19-CEBPα-saRNA conjugated aptamer or 1.29-fold (P = 0.015) and 1.4-fold (P = 0.026), respectively, by P1- CEBPα-saRNA-conjugated aptamer. (t-test with Welch's correction at 95% confidence interval). (d) A WST-1 cell proliferation assay was performed in PANC-1 cells. At 96 hours, only 22.9% of total cells were proliferating following treatment with P19-CEBPα-saRNA and 28% of total cells proliferation following P1-C/EBPα-saRNA. Both P19-Scramble-saRNA and P1-Scramble-saRNA demonstrated cytostatic effects on the cells. (e) Western blot analysis was carried out in PANC-1 cells treated with P19- or P1-conjugated C/EBPα–saRNA or scrambled saRNA aptamers. Membranes were probed with anti-C/EBPα and anti-actin (control). Band intensity from three representative blots was analyzed (right panel). P19 and P1- C/EBPα -saRNA treatment induced a threefold increase in CEBPA signal relative to untreated cells. P19 and P1-scramble conjugate treatment both induced a twofold increase in CEBPA signal.